Tags

Type your tag names separated by a space and hit enter

Treatment of Parkinson's disease.
Aust Fam Physician. 1995 Sep; 24(9):1685-7, 1690-2.AF

Abstract

Early stage Parkinson's disease may be better left untreated if it does not limit motor function. Once limitation of function is present levodopa-dopa decarboxylase inhibitor combinations are the most effective therapy, although amantadine may be satisfactory for a time in milder cases. The optimal independent roles of the ergot derivatives bromocriptine and pergolide, and the MAOb inhibitor selegiline, are not yet generally agreed although they are accepted as useful in supplementing the effects of levodopa. With prolonged levodopa use various late-stage treatment problems may appear. The pathogenesis of these is poorly understood and no completely satisfactory ways of managing them are available.

Authors+Show Affiliations

Department of Medicine, University of Queensland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7487655

Citation

Eadie, M J.. "Treatment of Parkinson's Disease." Australian Family Physician, vol. 24, no. 9, 1995, pp. 1685-7, 1690-2.
Eadie MJ. Treatment of Parkinson's disease. Aust Fam Physician. 1995;24(9):1685-7, 1690-2.
Eadie, M. J. (1995). Treatment of Parkinson's disease. Australian Family Physician, 24(9), 1685-7, 1690-2.
Eadie MJ. Treatment of Parkinson's Disease. Aust Fam Physician. 1995;24(9):1685-7, 1690-2. PubMed PMID: 7487655.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of Parkinson's disease. A1 - Eadie,M J, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez SP - 1685-7, 1690-2 JF - Australian family physician JO - Aust Fam Physician VL - 24 IS - 9 N2 - Early stage Parkinson's disease may be better left untreated if it does not limit motor function. Once limitation of function is present levodopa-dopa decarboxylase inhibitor combinations are the most effective therapy, although amantadine may be satisfactory for a time in milder cases. The optimal independent roles of the ergot derivatives bromocriptine and pergolide, and the MAOb inhibitor selegiline, are not yet generally agreed although they are accepted as useful in supplementing the effects of levodopa. With prolonged levodopa use various late-stage treatment problems may appear. The pathogenesis of these is poorly understood and no completely satisfactory ways of managing them are available. SN - 0300-8495 UR - https://www.unboundmedicine.com/medline/citation/7487655/Treatment_of_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -